{"entity":{"id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","aka":[],"tldr":"A phase 1/2 trial of CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg) in advanced solid tumours, run by Carrick Therapeutics Limited, now recruiting.","summary":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies is a phase 1/2 interventional study registered as NCT06600789 by Carrick Therapeutics Limited, with 50 participants planned, started 2024-08-16 and due to reach its primary completion in 2027-03-14. Interventions recorded: CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06600789","url":"https://clinicaltrials.gov/study/NCT06600789"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06600789","phase":"1/2","setting":"A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies","sponsor":"Carrick Therapeutics Limited","enrolled":50,"outcomes":[]},"route":"/trials/nct06600789/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}